Home › Long QT Syndrome › NCT04336644

Continuous Versus Intermittent cARdiac Electrical moNitorinG

Who can join

Ages 18 and older · All sexes

Inclusion Criteria:

* Diagnosis of acute promyelocytic leukemia (APL) and being initiated on standard of care arsenic trioxide OR Diagnosis of solid tumor and being initiated on standard of care capecitabine (alone or as part of combination treatment) OR Diagnosis of solid tumor and being initiated on standard of care ribociclib (alone or as part of combination treatment)
* At least 18 years of age.
* No allergy to adhesive patches.
* Able to understand and willing to sign an IRB-approved written informed consent document.

Exclusion Criteria:

* Younger than 18 years of age
* Allergy to adhesive patches

About the study

The purpose of this study is to validate the continuous patch monitoring system to evaluate cardiac arrhythmias in patients receiving drugs that can cause cardiac complications and compare the continuous patch system with standard electrocardiograms (ECGs).

What is being tested

• BodyGuardian Mini Plus (device)

Sponsor: Washington University School of Medicine · Participants: 60 · Started: Nov 21, 2023

Contact the study team

• Joshua D Mitchell, M.D., FACC · Phone: 314-494-3124
• Kaitlin Moore · Phone: 314-273-0830

Official record on ClinicalTrials.gov — NCT04336644

Locations in the U.S.

Conditions

• Long QT Syndrome

From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.